…Services for the purpose of creating another product or service; or access the Services in order to build a competitive solution or to assist someone else to build a competitive…
…Obviously, there’s just way too many people that have come before me in this kind of experience, but they’ve blogged and put up websites of their own experience. Just reading…
…information; and (iii) download Tapestri Insights™ software and publicly available data sets. Communications. If you contact us directly, we may receive additional information about you. For example, when you contact…
In the latest episode of On the Drop podcast, Mission Bio CMO Todd Druley, MD, PhD, discusses his career in pediatric oncology and molecular genetics, what drew him to Mission…
…www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they…
In our latest episode of On the Drop, Director of Product Development Nicole Ovadia discusses why measurable residual disease (MRD) is an issue and how our Tapestri scMRD Assay for…
…With this partnership, we can now offer complete support from preclinical and biomarker discovery through to clinical trials and commercialization.” “LabCorp’s leadership in precision medicine is based on a combination…
…Warranty) will be free from material defects in materials and workmanship under normal use for a period of one (1) year from the date Seller makes the device available for…
… Darrin Crisitello joins the Mission Bio team as Chief Commercial Officer with over 19 years of experience in commercial leadership and business development. Previously, Crisitello led the global clinical…
…matter what level of the organization she is in. Our latest project was evaluating our personalities. The participants took an online personality test (DiSC) to understand how we work and…
…and the product development life cycle of biotechnology instruments.” How was your experience at Mission Bio? Coming into this internship, I was excited for the opportunity to launch life-changing products…
…mechanisms of cancer showed me how committed everyone is to this gargantuan endeavor and how vital teamwork is. This experience gave me a better understanding of the work necessary to…
…& a Lack of Standardization The FDA requires multiple, different yet complementary assays to show the drug product is pure, safe and potent. However, given the complexity and composition of…
…full survey report here: https://go.missionbio.com/cgt-survey-report To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company…
…and how things work. That breadth rolls together into complicated systems. I’ve built systems that integrate the latest science and engineering, from software to hardware. At Mission Bio, I wanted…
…company, but to broader society. I think all of us actually have a part in that regardless of your position, regardless of where you are at in the company. If…
…terms of how prevalent this problem was and had us examine our experience at Stanford since 2016, looking to see how many patients we’ve given various cell therapies to and…
…sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company. His experience in driving organizational transformation and large-scale commercial growth, coupled with his…
…generated with the Tapestri Pipeline software to meaningful fish plots using Tapestri Insights. Visualize the thousands of data points intuitively and simply with Mission Bio’s Tapestri Insights software. Part 1/3….
…In some cases, cells may be genetically modified prior to expansion and infusion into the patient. These therapies are a combination of gene therapy and cell therapy. A notable example…
Single-cell analysis has enabled the comprehensive characterization of tumor samples, especially for blood cancers like leukemia. Using the Tapestri Platform, for instance, enables researchers to dissect the clonal structure of…
…Bio. The company expanded its capabilities, welcomed new leadership, and enabled groundbreaking research. Here are a few of the highlights: 1. Welcoming a New CEO In April Yan Zhang, Ph.D….
…single-cell DNA sequencing of longitudinal AML tumors totaling over 500,000 cells. In addition to seeing an association of increased heterogeneity with worse clinical outcomes when comparing baseline and remission samples,…
…To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for…
…The online version of the full peer-reviewed study can be found here. To learn more about Mission Bio and how it’s moving precision medicine forward, visit www.missionbio.com. About Mission…
…unique and novel custom panel needs for single-cell DNA or multi-omics panels. This latest milestone comes on the heels of a landmark year for Mission Bio’s work to support…
…day come to be? As many of us are familiar, when it comes to participation in science there is a rift between the genders. Only about a third of scientific…
…But recent studies have warned about the dangers of unintended genome alterations and how they could negatively impact patient outcomes. Altering genetic material is complex, and researchers need to be…
…outcomes in the fight against cancer — and that’s the most meaningful benchmark of all.” The funding round comes a year after the company’s commercial launch of the Tapestri Platform…
Untangle the Complexity of Cancer. Determine the sources of resistance, response, and relapse Tapestri single-cell DNA panels and protein panels are highly sensitive and customizable panels that enable true multi-omics…
…stages of evolution that bulk sequencing missed,” said Ferran Nadeu, PhD, a postdoctoral researcher at IDIBAPS and the publication’s primary author. “This is the latest example of how the…
…progression and develop more precise therapies. The commercial launch of Mission Bio’s Tapestri Solution for Solid Tumor Research highlights the company’s continued dedication to enabling cancer research at a…
…first treatments[1]. Currently, flow cytometry and single gene testing, and bulk next-generation sequencing are used to detect the presence of measurable residual disease (MRD). However, even if both tests come…
…Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled…
…inadequate to fully characterize somatic variation buried in the landscape of cellular populations. Single-cell targeted DNA sequencing provides an essential solution to elucidate and map genomic variation in such materials….
…on both the sensitivity and specificity of commercial MRD tests used today both in research and to predict cancer recurrence in patients, leveraging the Tapestri® Platform’s unique ability to measure…
…concerns due to its potential to trigger tumorigenesis during CAR-T therapy. To mitigate this issue, characterization of vector integration on clonal expansion after gene therapy has become a crucial practice…
…and in which cellular compartment they reside. This is the type of work the Tapestri instrument is made for. By combining DNA mutational analysis and immunophenotyping, one can simultaneously measure…
…monitor clonal evolution, as this approach requires complex computational analysis. Researchers could greatly expand their knowledge of changes occurring at the DNA level by the addition of single-cell DNA-seq. Moreover,…
…be designed quickly and easily to complement Tapestri Single-Cell DNA Catalog Panels. The announcements come on the heels of a peer-reviewed publication by Mission Bio and MD Anderson Cancer…
Single cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells, however most genomic regions characterized in single cells are non-informative. To overcome this issue, we…
…disease lies in its complexity. Tumors are composed of subpopulations of cells — or clones — that each has a unique collection of mutations. It is this heterogeneity coupled with…
…investment group focused solely on biotechnology, genomics, diagnostics, medical device and mobile health companies. Since 2005, LSA and its affiliates have invested over $50 million in 50 companies which have…
…cell. Characterize genomic heterogeneity using a single platform, with comprehensive single-cell SNV and CNV analysis to co-detect all the changes in our blueprint. When determining the clonal heterogeneity across a…
…disease evolution can influence treatment outcomes. By examining over 500,000 cells from 77 patients, the study uncovered the impact of linear versus branched evolutions on treatment success, emphasizing the superiority…
…clones expanding (green dots) and shrinking (red dots) over time, and then assess the commonalities between the green dots and commonalities amongst the red dots. This example shows pre-treatment samples…
…and evolutionary trajectories in cancers at the single-cell level and presents his latest findings in breast cancer research. This webinar also presents the latest advances in single-cell DNA sequencing, including…
…with a different relationship to complex diseases like cancer: a world where cancer is manageable, even curable. With this latest capital, we’re on track to make that vision a reality….
Darrin Crisitello, Chief Commercial Officer, Mission Bio At Mission Bio, everyone at the company is pushing forward with science that can improve patient care in a meaningful way. Upon recently…
Inactive state-selective KRAS(G12C) inhibitors1-8 demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class…
…visit https://go.missionbio.com/ash-2022. To meet us in person, please visit us all week at Booth 2014. To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. …
…of the Tapestri platform in our clinical laboratories.” The latest partnership builds on Mission Bio’s commitment to providing high-quality single-cell multi-omics with the Tapestri platform globally, recently demonstrated through a…
…loss, one thing came to the forefront that should never be forgotten: when put to the test against all odds, today’s scientists can come together to accomplish the seemingly impossible….
…ASXL1, collectively referred to as DTA mutations (incorporating the first letter of each gene). HSCs with these mutations have a competitive advantage, such that they are able to self-renew more…
…the presence of additional mutations does not influence the selection of TP53 mutant cells by MDM2 inhibitor treatment. Also, we describe an in vitro test allowing to predict the emergence…
…Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com. About Rigosertib Rigosertib, Onconova’s lead…
…clinical and enterprise computing security best practices (Reference; https://aws.amazon.com/compliance/soc-faqs/). Mission Bio’s AWS security policies MissionBio provides an AWS-based platform for client use following best practices in the following areas Identity…
…determining CQAs 56% feel dissatisfied with their characterization approach 81% agree better characterization would reduce risk of holds Download The cell and gene therapy characterization survey report to learn more….
…of residual or recurring cancer.” To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company…
…promising drug that is currently in advanced clinical development,” said Yan Zhang, PhD, CEO of Mission Bio. “But it’s just the latest example of how Tapestri can help discern when…
…about Mission Bio and the Tapestri platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of…
…same editing regimen can yield distinct combinations of edits, varying not only across multiple on-target sites but also between on-target and off-target locations. The result is that genome editing of…
…tissue. Snap freezing or OCT embedding tissues are the most common forms of preservation. However, these methods add an additional layer of complexity to sample preparation. Some researchers have addressed…
…building high-growth companies. His prior roles include founder, CEO, executive board director, division president at large publicly traded and PE-backed companies such as Fortis Life Sciences, LGC, PerkinElmer, Life Technologies,…
Roman is the Chief Commercial Officer at Mission Bio. Roman has more than 25 years of experience in diagnostics and life sciences research, including previous roles as EVP and General…
Marlene Martinez leads the human resources team focusing on attracting, retaining, and developing our talent as we scale as an organization. She has over 15 years of experience in human…
Ben Schroeder has over 20 years of experience in biotechnology R&D. His focus has been novel genomic technologies spanning small start-ups to large established companies. Ben started his career at…
Hannah Viernes leads the marketing team and has over 15 years of experience across life sciences tool companies in both product management and marketing. Most recently, Hannah led the Global…
…on the safety of the therapy. Tapestri® v3 is the latest example of Mission Bio’s continued focus on customer-centric product and service development. The company has recently implemented additional…
…combined with a false-negative rate as low as 7% scTAM-seq can be combined with somatic mutation and cell surface expression analysis to enable a much richer characterization of tumor heterogeneity…
Single-cell DNA methylation profiling currently suffers from excessive noise and/or limited cellular throughput. We developed scTAM-seq, a targeted bisulfite-free method for profiling up to 650 CpGs in up to 10,000…
…in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the…
…value in leading a world-class team that can execute with precision, humility, and humanity. Yan’s experience, vision, and proven track record are a great combination for leading Mission Bio into…
…therapies continue to hold tremendous promise for hard-to-treat diseases but have encountered safety questions associated with genomic stability. The latest FDA guidance suggests that assessment of genomic integrity include chromosomal…
…will provide customers with early access to services based on the latest new technological innovations, in addition to services on Mission Bio’s existing products to implement Single Cell Multiomics capabilities…
…in uncovering these significant insights into FLT3 inhibitor resistance in AML.” Today’s announcement is the latest of several published studies that have utilized Mission Bio’s Tapestri Platform to power…
…the promise of multi-omics tools for advancing treatments for leukemia and other cancers. “Today’s publication in Nature Communications is the latest in a growing number of studies that demonstrate how…
…data reveal that pediatric patients carrying germline SAMD9/9L mutations can potentially self-correct without the need for an invasive bone marrow transplant. “These latest findings reinforce the power of single-cell studies,…
…Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)–evaluable patients (N = 16), 63% attained MRD-negative remissions;…
…observed at diagnosis in both cohorts; however, decreasing clonal diversity at remission was significantly associated with longer relapse-free survival. These results show the power of SCS in investigating AML MRD…
…of the Centre for Genomic Regulation (CRG) in Barcelona teamed up to develop a novel high-throughput, high-confidence targeted bisulfite-free method for analyzing DNAm in single cells, now published in Genome…
…key pathological feature. Tumors comprise multiple genetically-distinct cell populations, called clones. And the mutations of each clone are often of clinical significance. For instance, some co-mutations may give a clone…
…the tumor microenvironment. Importantly, the presence of monocytic MDS-PA at diagnosis anticipated greater risk of hematologic toxicity and was independently associated with inferior progression-free survival (hazard ratio, 1.5; P =…
New Chair brings extensive financial and life sciences experience with industry-leading companies SOUTH SAN FRANCISCO, March 17, 2022 — Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics…
…interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein…
…and the Tapestri Platform, please visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio Appoints Roman Haehn as Chief Commercial Officer to Drive Market Expansion…
…This announcement follows on the heels of the successful launch of the company’s scMRD Assay, to which the latest data on 48 samples from the Clínica Universidad de Navarra will…
…the current workflow. With this latest capability, Mission Bio’s Tapestri® Platform now stands as the first and only commercial platform for single-cell DNA analysis, with comprehensive insight into mutations and…
…of TIBSOVO resistance supported clinical findings of the pivotal TIBSOVO-azacitidine combination trial in IDH1-mutant AML, and the combination was approved by FDA in May 2022. Partnership will continue to generate…
…world’s leaders in life sciences supporting our commercialization efforts,” says Darrin Crisitello, Chief Commercial Officer of Mission Bio. “Leveraging Agilent’s vast US commercial footprint gives us significant reach to additional…
…relapse. Equipped with single-cell DNA sequencing and other innovative technologies, oncologists and researchers are working hard to bring better treatment to blood cancer patients. References https://www.lls.org/facts-and-statistics/facts-and-statistics-overview https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21654 https://www.medscape.com/answers/199425-167660/what-is-the-prognosis-of-chronic-myelogenous-leukemia-cml …
…clinical utility.” To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Abiosciences Abioscience is a biotechnology company with a global vision founded in…
Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) are highly heterogeneous diseases with many variable subtypes and molecular profiles. Thus, they pose complex challenges, requiring innovative approaches for diagnosis, monitoring,…
Chris Mason is Founder and CSO at AVROBIO, Inc. a clinical-stage, gene therapy company [NASDAQ AVRO]. He is a clinician-scientist with 30 years of cell and gene therapy experience spanning…
…and predict relapse. Speakers will share the strategies they employ to characterize heterogeneity in cancers at the single-cell level. Presenters: Tractable combinatorial genetics accelerates the functional annotation of cancer genotype-phenotype…
As the CEO of Mission Bio, Yan Zhang has more than 15 years of experience in commercial team management, product management, business development, and marketing. Recently, Yan shared her perspectives…
Sequencing has revolutionized cancer research – are you still just using bulk sequencing? What are you missing? Find out about the latest and greatest work in single cell DNA sequencing…
…Regulatory guidance, best practices, and forward-looking considerations in early drug development that can lead to process improvements Mitigating clinical holds Latest technologies and innovative approaches in CGT development and manufacturing,…
In this virtual seminar, Dr. Sandra Misale of Memorial Sloan Kettering Cancer Center presents data from her latest publication “Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal…
…ASGCT and ISCT provides a unique opportunity to witness the latest advancements and breakthroughs in the fields of cellular therapy, regenerative medicine, and gene therapy. The recent editions of these…
…of the Tapestri Genome Editing Solution, be sure to check out our latest white paper. It offers an in-depth exploration of the pipeline’s capabilities, its impact on genomic analysis, and…
…Sickle Disease. However, the power of CRISPR comes hand-in-hand with a complex challenge – the inherent heterogeneity in editing outcomes. This variability can pose a significant hurdle for researchers aiming…
…mix and mingle, sharing their latest advancements and insights in the rapidly evolving field of cell and gene-based therapy. Attendees were treated to engaging discussions and networking. This event not…
…conferences. CASSS: Bridging Biopharma and Regulatory Bodies At the CASSS CGPT Meeting, the presence of both biopharma companies and regulatory bodies highlighted a critical need for comprehensive characterization data. The…
…relationship to complex diseases like cancer: a world where cancer is manageable, even curable. With this latest capital, we’re on track to make that vision a reality. …
…latest system extends Mission Bio’s market reach, merging the $3 billion flow market with the $2.5 billion next-generation sequencing market. The combined market is projected to reach over $20 billion…
…Thank goodness the content will be available until June for continued viewing. As Mission Bio’s customers span all aspects of translational research, I wanted to hear the latest on prognostic…
…Applications, Aaron Llanso in Vienna. They shared the latest advancements in single-cell DNA sequencing, particularly in the field of single-cell Minimal Residual Disease (scMRD), Clonal Hematopoiesis, and Therapeutic Resistance during…
With the latest additions and improvements to Tapestri’s capabilities, researchers of hematologic oncology can now access single-cell insights from as few as 20,000 cells, while conserving precious samples. Get up…
…2018 list recognizes the latest and greatest tools, technologies, and techniques to hit the life-science landscape. And while 2018 was a banner year for single-cell innovation, we are proud that…
Find the key signatures of cancer. Cancer is a complex disease, where behind its complexity lie meaningful insights to source and its cure. Bulk sequencing erases cancer’s fundamental units, individual…
Hematology. Because single-cell insights are critical to determining the source of resistance, response, and relapse It is time to get a holistic view of cancer The complexity of cancer is…
Solid Tumor. Because clonal phylogeny and rare cell detection contribute to disease evolution It is time to look at the sources of maligancies Solid tumors often show multiple levels of…
Genome Editing. Because zygosity and co-occurrence of multiple on and off-edit targets make a difference It is time to unlock biological complexity Genome editing libraries are powerful tools to advance…
…can unravel the mechanisms that drive disease correction and disease progression, visit missionbio.com. ———————————————————————– 1 https://www.cancer.gov/research/key-initiatives/ras/about About Mission Bio Mission Bio is a life sciences company that accelerates discoveries…
…in research institutes, hospitals, and pharmaceutical companies worldwide, to promote adoption of innovative single-cell omics technologies to clinical diagnosis, drug development, and health management. For more information, visit www.sequmed.com. …
…life science research, healthcare, and agriculture. For more information about S2 Genomics and the Singulator 100, visit www.S2Genomics.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio…
…more information about Tapestri, please visit www.missionbio.com. About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis….
…to treat is that the disease inherently has many different molecular drivers and indicators. MM is a genetically complex malignancy comprised of immunoglobulin translocations, focal and genome-wide CNVs, complex genomic…
…To learn more about Mission Bio and how it’s moving precision medicine forward, visit www.missionbio.com. About Mission Bio Mission Bio delivers targeted solutions for high impact applications with the…
…& Gene Meeting on the Mesa in Carlsbad, CA. To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is…
…the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping…
…Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases…
…concern, the pressing need for effective SCD treatments urges continued research, monitoring, and careful consideration of the benefits against the risks in advancing such transformative therapies. Sources https://www.genengnews.com/topics/genome-editing/crispr-prime-time-fda-advisory-committee-evaluates-vertex-exa-cel-therapy-for-sickle-cell-disease/ https://endpts.com/uk-approves-vertex-crispr-therapy-for-sickle-cell-disease-beta-thalassemia-in-world-first/…
…The company has partnered with BioLegend, a global leader in protein antibody and reagent manufacturing, to co-develop the first commercial solution for combined DNA and protein analysis at the single-cell…
Untangle Single-cell SNV and Indel Insights. The Tapestri Platform is the first and only single-cell multi-omics platform to simultaneously detect single nucleotide variants (SNVs) and indels from the same cell….
…companies looking to advance their understanding of cancer and develop more durable therapies with Mission Bio, visit missionbio.com. About Mission Bio Mission Bio delivers targeted solutions for high-impact applications…
…clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype…
Single-cell sequencing is like looking at the galaxy with the Hubble telescope. It provides the ability to drill down into the complexity of a cell in an environment where each…
DNA is the template for human biology and the point where a single mutation initiates disease. By taking a holistic approach, we can investigate every part of the cell and…
…physics and applied it to droplet manipulation, ultimately co-developing the technology that became the core of Mission Bio. He continues to be interested in tackling complex, interdisciplinary problems with physics….
Anjali is Chief Product Officer at Mission Bio. She has launched cutting-edge products in DNA sequencing, RNA ISH, and multiplexed tissue imaging solutions. She has successfully developed and executed product…
…leadership roles at companies in the genomics space and in stem cells and regenerative medicine. Prior to joining Mission Bio, George led the sales team at Cellular Dynamics, where he…
…somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of…
Studies of acute myeloid leukemia rely on DNA sequencing and immunophenotyping by flow cytometry as primary tools for disease characterization. However, leukemia tumor heterogeneity complicates integration of DNA variants and…
Vascular malformations are considered monogenic disorders that result in dysregulated vessel growth. Cerebral cavernous malformations (CCMs) arise owing to inactivation of the endothelial CCM protein complex required to dampen MEKK3…
Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with…
…alterations and increased sensitivity to extracellular signal-regulated kinase inhibition. These findings identify an approach that abrogates the nongenetic resistance trajectory in melanoma and demonstrate that the cellular composition of MRD…
…bone marrow single-cell DNA sequencing revealed multiple competing SGR events in individual patients. Our findings demonstrate that SGR is common in SAMD9/9Lmut MDS and exemplify the exceptional plasticity of hematopoiesis…
Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation…
…familial CCM. Furthermore, we find identical PIK3CA mutations in CCMs and adjacent developmental venous anomalies (DVAs), a common vascular malformation frequently found in the vicinity of sporadic CCMs. However, somatic…
Todd Druley, MD, PhD established his career as a board-certified pediatric oncologist and tenured physician-scientist in molecular genomics at Washington University School of Medicine and St. Louis Children’s Hospital. Todd’s…
…unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up…
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL, we find that, despite a generally low…
…immune selection in HIV-1 reservoir cells,” published on January 4 in Nature. To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio…
…a phenotypic signature primarily characterized by upregulation of surface markers promoting cell survival, including CD44, CD28, CD127 and the IL-21 receptor. Together, these results suggest compartmentalized phenotypic signatures of immune…
Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture of normal and tumor cells, and/or of distinct tumor subclones; high-throughput single-cell DNA sequencing…
…base editing mutagenesis. Deep mutagenesis of JAK1 with cytidine and adenine base editors, combined with pathway-wide screens, reveal loss-of-function and gain-of-function mutations, including causal variants in hematological malignancies and mutations…
Adam is a co-founder and the interim Chief Operating Officer of Mission Bio. His proprietary research in high throughput and droplet technology helped lay the foundation for Mission Bio’s single-cell…
Pediatric acute myeloid leukemia (pAML) is typified by high relapse rates and a relative paucity of somatic DNA mutations. Although seminal studies show that splicing factor mutations and mis-splicing fuel…
Recent data suggest that NPM1-mutated AMLs are heterogeneous in terms of co-mutations and expression of transcriptomic programs and surface proteins. Such heterogeneity may reflect a variable differentiation blockade of leukemic…
…readouts and separately for characterization of editing outcomes through pooled single-cell genotyping. We efficiently design improved leukemia immunotherapy approaches, comprehensively identify non-coding variants modulating fetal hemoglobin expression, define mechanisms regulating…
…or are not applicable to targeted sequencing. Here, we develop COMPASS, a computational method for inferring the joint phylogeny of SNVs and CNAs from targeted scDNAseq data. We evaluate COMPASS…
…around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform…
…cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the same sample…
…utility. For more information on the Single-cell Tapestri® Genome Editing Solution, visit https://missionbio.com/applications/genome-editing/ About Mission Bio Mission Bio is a leading life science company, specializing in the advancement…
…medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and…
…unmatched resolution, please visit missionbio.com/products/platform/. About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company’s Tapestri…
…of multiple concurrent mechanisms in individual patients underscores the complex biology of resistance and has important implications for rational combination therapy design. This trial was registered at www.clinicaltrials.gov as #NCT02074839….
…Day on April 21 each year, they have been campaigning annually to increase understanding of AML and bring attention to the resources available for the community. At Mission Bio, our…
…spotlight on the challenges that women face. From the Me Too movement to greater awareness of gender bias in the workplace, we have come a long way from just a…
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the…
Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations…
Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture of normal and tumor cells, and/or of distinct tumor subclones; high throughput single-cell DNA…
During the course of infection, human immunodeficiency virus (HIV) maintains a stably integrated reservoir of replication-competent proviruses within the host genome that are unaffected by antiretroviral therapy. Curative advancements rely…
…cellular compartments depending upon co-occurring mutations. These studies provide a path to model sequential mutagenesis and deterministically investigate mechanisms of transformation and oncogenic dependency in the context of clonal evolution….
…precursors remains a challenge with current MRD tools. Herein, we developed a single cell (sc) MRD assay by combining flow cytometric enrichment of the targeted precursor/blast population with integrated scDNA…
…MIF modifies TET2 CH cardiovascular disease risk. Using mitochondrial lineage tracing, we used a novel method to compare gene expression between mutated and non-mutated cells within individual CH patients. We…
…role in hematopoietic stem cell differentiation and monocyte lineage commitment. Together, these data provide a mechanistic insight to the poor prognostic value of clonal hematopoiesis in patients infected with Sars-COV2….
…sensitive and customizable solution that is fully supported to enable meaningful discoveries. Media Contact: Andrea Vuturo andrea@vuturo.com (415) 689-8414 Mission Bio: Rebecca Galler Senior Vice President, Marketing galler@missionbio.com (303) 887-7658…
…Coast Angels and Keiretsu Forum, as well as other seed-stage investment funds. For more information on Mission Bio, please visit missionbio.com. About Mission Bio, Inc. Mission Bio, Inc. is innovating…
…biology. In October 2017, the company announced its Series A funding to support the commercialization of Tapestri. To learn more about Mission Bio and how it’s moving precision medicine forward,…
…comes on the heels of Mission Bio’s recent expansion into single-cell multi-omics, launching the industry’s first and only capabilities to detect DNA and protein changes simultaneously from the same cell…
Cancer is a heterogeneous mixture of cells with varied states. The best treatment options require an understanding of the disease state at the cellular level. Single-cell multi-omics reveals the interplay…
Cancer begins in a single cell within the DNA. These genetic mutations are often caused by single nucleotide variants (SNVs) and gene copy number variants (CNVs), including loss of heterozygosity…
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a single-cell multi-omics approach…
…data resolves the complexities of mutation zygosity and co-occurrence in a genome-editing experiment targeting multiple loci. The Tapestri Platform offers a turnkey solution to the complex challenge of characterizing genome-edited…
…discern clonality and resolve mutational co-occurrence patterns. Dr. John Lee, of Fred Hutchinson Cancer Center, sought to better understand which combinations of mutations were critical by leveraging a mouse model,…
An average readout from conventional bulk sequencing misses the underlying genetic diversity across cell populations. The Tapestri Platform was developed to enable the accelerated and accessible detection of genomic variability…
…a more comprehensive picture of the disease progression. Distinguishing mutational status at the single-cell level offers precision in diagnosis and informs treatment options. Learn how the Tapestri Single-cell DNA AML…
Recent advancements in genomic analysis of tumors have revealed that cancer disease evolves by a reiterative process of somatic variation, clonal expansion, and selection. To identify lower-prevalence mutations, very high-level…
Co-occurrence and zygosity of mutations in subclonal populations are frequently missed with bulk sequencing. In high-count monoclonal B-cell lymphocytosis (MBL), these mutations were detectable across all patient samples, on average…
Cell and gene therapies are yielding new treatments, which were inconceivable only a few decades ago, for genetic disorders including cancers and inherited diseases. Single-cell DNA sequencing on the Tapestri…
…allows for the rapid optimization of gene transfer protocols during therapy development and for streamlined testing for batch release. A version written in Mandarin is also available here. …
…co-mutations responsible for tumorigenesis. The following are covered: Assessment of precise genetic edits Analysis of the clonal structure & co-mutations of AEL Use of CRISPR and scDNA-seq for disease modeling…
…we show that MGI and Illumina platforms are equally compatible with the Tapestri Platform for single-cell DNA sequencing. A version written in Mandarin is also available here. The following are…
…every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously,…
…research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer. To learn more, visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Tapestri Cell…
…it with additional experts as we shine a new light across the solid tumor landscape.” To learn more, visit missionbio.com. About Mission Bio Mission Bio is a life sciences company…
… For more on Mission Bio and the Tapestri platform, please visit missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for…
…Mission Bio’s commitment to continuously developing innovative single-cell technologies for its pharma customers. “We have seen tremendous uptake and interest from top-tier pharma companies for our blood cancer Pharma…
…Platform, please visit missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with…
…About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities,…
…patient outcomes in the future.” About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omics analysis. The company’s Tapestri…
…be combined or purchased separately to suit the user’s needs. These assays are compatible with the existing Tapestri Instrument, v3 chemistry, and sample multiplexing: Multiple Myeloma DNA Panel, a…
…cell populations at unprecedented resolution compared to traditional bulk sequencing approaches. Starting the design process is easy, and panel designs can be completed within a matter of minutes. To begin,…
…in Melbourne, Australia, highlights co-occurring therapy-driven mutations that stand to impact future treatment strategies and combinatorial approaches. The findings were published in Blood, the peer-reviewed medical journal of The American…
Cancer is a complex disease with a mix of cells with varied states, and understanding of the disease state at the cellular level is required for better therapies. A single-cell…
…missed by standard bulk sequencing or identifying co-mutation patterns and zygosity in subclones, Tapestri Single-cell DNA panels and protein panels can be applied across a wide range of discovery and…
…the clonal heterogeneity of cancers or the performance of gene-editing protocols across thousands of single cells. Our Tapestri Designer software allows you to complete custom designs quickly and easily. …
High-throughput single-cell DNA sequencing is essential to assess genetic variations in rare cells and better understand the role they play in the evolution of tumor progression. To address these challenges…
It is essential to develop new capabilities for assessing genetic variation present in rare cells and to better understand the role that these cells play in the evolution of tumor…
Many stages of hematopoietic differentiation provide multiple opportunities for mutations that lead to distinct tumor subtypes. However, standard bulk population sequencing is hard to identify rare alleles or determine whether…
Understanding tumor heterogeneity and clonal evolution has major implications in oncology research. Both chromosomal structural change/copy number alteration/variation (CNA/CNV) and driver gene mutation events are critical in cancer initiation and…
To improve variant calling and minimal residual disease (MRD) detection we developed a novel consensus sequence-based method for correcting the errors and reducing the false-positive rates….
…in targeted therapy selection and disease monitoring. Single-cell sequencing has the potential to provide unique insights on the cellular and genetic composition, drivers, and signatures of cancer at unparalleled sensitivity….
High-throughput single-cell DNA sequencing allows for the detection of rare mutations in cells and identification of sub-clones defined by co-occurrence of mutations. The big challenge with multiplex sequencing at the…
AML has a poor prognosis, mainly due to relapse. Single-cell DNA sequencing technologies like the Mission Bio Tapestri Platform enable us to understand the clonal heterogeneity of AML patient samples…..
Recent advancements in genomic analysis of tumors have revealed that cancer disease evolves by a reiterative process of somatic variation, clonal expansion, and selection. Therefore, intra- and inter-tumor genomic heterogeneity…
Single-cell technologies have advanced our approach to precision medicine, improving our understanding of the genetic variation and drivers of cancer with sensitivity that bulk sequencing cannot provide….
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a multi-omics approach is…
Single-cell sequencing elucidates unique insights in understanding intratumor heterogeneity and clonal evolution. Both chromosomal structural change/copy number alteration/variation (CNA/CNV) and driver gene mutation events appear somatically at the early stages…
…resolution of the disease at the cellular level, revealing the interplay between genotype and phenotype. The Tapestri Platform enables comprehensive identification of cell subpopulations through single-cell multi-omics profiling. The platform…
Through single-cell sequencing technologies, it is now possible to interrogate thousands of cells in a single experiment for genetic variability. Single-cell DNA platforms like Tapestri are still susceptible to errors…
High throughput single cell DNA targeted sequencing enables the detection of rare mutations in cells and the identification of subclones defined by co-occurrence of mutations. The big challenge with multiplex…
…most common childhood leukemia. The T-cell subtype (T-ALL) is the more rare and aggressive form of ALL, and patients who relapse have limited therapeutic options and a poor prognosis. While…
In tandem, the company expands into Europe through partnerships with leading research and medical institutions to help them predict and prevent cancer relapse SOUTH SAN FRANCISCO, Calif. (March…
…biology and subsequent therapy development. The additional ability to examine the correlation between mutations and protein expression patterns at the single-cell level gives a more complete understanding of cancer, with…
…were analyzed, and more than 700,000 cells were sequenced. They determined that the level of clonal complexity rises with disease progression. In particular, not all mutation combinations are equal, and…
We recently spoke with Dr. Cummins about her research, use of the Tapestri Platform, and thoughts on single-cell multi-omics and cell therapies for leukemias….
We recently spoke with Dr. Smith about her research, use of the Tapestri Platform, and thoughts on the clinical potential for routine, high-throughput single-cell DNA analysis….
On World AML Day, we had the pleasure of being joined by Dr. Ross Levine of Memorial Sloan Kettering Cancer Center to discuss the use of single-cell technology and how…
…DNA to reveal extensive proteogenomic decoupling in leukemia patient samples. Now cell types and cell states are revealed by combining protein markers with DNA analysis from thousands of single cells….
…better understand which combinations of mutations are important for driving bladder cancer, Dr. John Lee from the Fred Hutch Institute combines sophisticated genome editing, organoid, and mouse model approaches with…
Minimal Residual Disease (MRD) detection and monitoring hold great promise to be used in clinical trials and beyond patient therapy selection. If single nucleotide variants (SNVs) are detected early on,…
Challenging the dogma that single nucleotide variants (SNVs) in RNA splicing factors do not occur in the same cell due to their synthetic lethal interactions and/or convergent effects, Dr. Justin…
Have you ever wondered what were the exact indels that were made to the DNA after genome editing experiments? Have you wondered what percentage of the cells had certain edits?…
Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumors have significant clinical implications. In this eBook, review how single-cell DNA…
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a multi-omics approach is…
…genetic composition. This poster presents the process of Mission Bio’s Tapestri Platform, which enables high-throughput targeted DNA sequencing in single cells to obtain single-nucleotide variation (SNV) and copy number variation…
Understanding the genomic landscape of cancer in single cells can be valuable for understanding tumor evolution and developing treatment regimens. This poster presents a muli-modal approach on the Tapestri Platform,…
This poster demonstrates the capability of the Tapestri Platform multi-omics workflow (which analyzes the DNA and protein information from the same cells) to discriminate cell populations. Using a two-donor PBMC…
…we show that MGI and Illumina platforms are equally compatible with the Tapestri Platform for single-cell DNA sequencing. A version written in English is also available here. The following are…
Cell and gene therapies are yielding new treatments, which were inconceivable only a few decades ago, for genetic disorders including cancers and inherited diseases. Single-cell DNA sequencing on the Tapestri…
The Tapestri Platform provides an unprecedented level of quantification of DNA integrations in significantly less time compared to other techniques such as qPCR and does so at single-cell resolution. These…
At Mission Bio, we applaud the research that has been accomplished over the years using our innovative single-cell multi-omics platform, Tapestri. We compiled a list of publications that utilize single-cell…
Acute lymphoblastic leukemia (ALL) is characterized by the presence of chromosomal changes, including numerical changes, translocations, and deletions, which are often associated with additional single-nucleotide mutations. In this study, we…
The inclusion of intracellular protein detection enables the measurement of pivotal proteins in cancer mechanisms, including apoptosis (BCL2 family proteins), transcription factors (GATA3), tumor suppressors (TP53), as well as phosphorylated…
There is a lack of data on CNV in single cells in solid tumor samples. We demonstrate single-cell DNA sequencing using the Tapestri instrument for solid tumor samples and an…
Cell and gene therapies are transformative solutions for diseases where existing interventions are ineffective. Many such therapies rely on the introduction of transgenes into host cells using viral or non-viral…
Cancer is a disease driven by genomic mutation and selection. While the advent of next generation sequencing has revolutionized genomic analysis, the data obtained from bulk sequencing do not represent…
CRISPR is a powerful tool for the development of novel cell and gene therapies. Despite its ability to precisely alter the genome, CRISPR can yield off-target edits and rare chromosomal…
…of Excellence for Solid Tumor. • The Tapestri Platform, combined with the new Tapestri Single-cell CNV Analysis Tool, enables co-measurement of single-cell SNVs and CNVs across thousands of single cells….
…safety and efficacy. Yet, conventional methods for measuring gene transfer lack the resolution and representation to truly reflect sample composition and either report a population average (bulk) or involve laborious…
…for 1/3rd of all meningiomas. NF2-wild type meningiomas are commonly associated with mutations in SMO, POLR2A, PIK3CA, AKT1, and KLF4 mutations, the latter both occur regularly with TRAF7 mutations. The…
Internal tandem duplication of the Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 (FLT3-ITD) is one of the most clinically relevant mutations in acute myeloid leukemia (AML), with a high FLT3-ITD…
…copy number (VCN). Yet, conventional methods for measuring gene transfer lack the resolution and representation to truly reflect sample composition and either report a population average (bulk) or involve laborious…
…of Excellence for Solid Tumor. • The Tapestri Platform, combined with the new Tapestri Single-cell CNV Analysis Tool, enables co-measurement of single-cell SNVs and CNVs across thousands of single cells….
Accelerate your hematologic oncology projects with a dedicated partner across the drug development pipeline through the Pharma Assay Development Biomarker Discovery pilot program….
Servier worked with Mission Bio’s Pharma Assay Development (PAD) services to utilize the Tapestri® single-cell DNA sequencing technology to serially assess hundreds of samples from patients with IDH1-mutated AML who…
…globe the power to interrogate genotype and immunophenotype together in individual cells, providing a comprehensive understanding of activity from a single sample. Tapestri® is the only commercialized multi-omics platform capable…
…their safety and efficacy. Yet, conventional methods for measuring gene transfer lack the resolution and representation to truly reflect sample composition and either report a population average (bulk) or involve…
…patients, the same blood samples were also studied for comparison by Tapestri single-cell DNA sequencing (scDNAseq). The clonal architectures derived by the 2 methods showed good overall concordance. scDNAseq showed…
…clonal outgrowth steps and hours of computational work. With the Tapestri single-cell platform you can rapidly capture genome editing outcomes and confidently validate your engineered cell therapy or CRISPR-based disease…
…aspects of therapy characterization. The Tapestri Platform enables multiple genotypic and phenotypic attributes to be co-measured across 1000s of individual cells. This high-throughput platform collapses multiple assays into one workflow,…
…gene editing, Tapestri can co-measure these attributes simultaneously in each cell. The platform’s powerful multi-omics capability enables the co-analysis of DNA and cell-surface proteins so you can evaluate cell type/…
…safety and efficacy. Yet, conventional methods for measuring gene transfer lacks the resolution and representation to truly reflect sample composition and either report a population average (bulk) or involve laborious…
…viral vector copy number (VCN), needs to be accurately measured. Yet conventional methods for measuring gene transfer lack the resolution and representation to truly reflect sample composition and either report…
Cell and gene therapies are notoriously difficult to characterize. Yet, early and thorough characterization is key to advancing therapeutic programs quickly with minimal risk of safety issues or clinical holds….
…was entirely surmised by mutated clones. BP originated from increasing clonal complexity, either on top or independent of a driver mutation, through acquisition of novel mutations as well as accumulation…
…but also identify putative DNA or protein targets for salvage therapy. By combining high sensitivity with multiomics, this assay provides researchers with comprehensive and clinically actionable insights into AML MRD….
…MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles bring unprecedented clarity to the complex biology…
…a significant proportion of patients in complete remission subsequently relapse and succumb to the disease. Measurable residual disease (MRD) testing has become the standard in AML and other cancers to…
…surface protein expression. We show here complex clonal evolution of MM in two patient samples as copy gains and losses were sequentially acquired and correlated with expression changes of MM…
Mission Bio’s Tapestri® Genome Editing Solution offers a comprehensive solution for high-throughput analysis of genomic edits at single-cell resolution. Here, we showcase the robust performance of the pipeline for both…
…heterozygous, compound heterozygous), and their functional impact all contribute to the layer of complexity in the mosaicism of editing outcomes. Current genome editing analyses primarily rely on bulk methods, which,…
Acute myeloid leukemia (AML) is a complex disease with a diverse genetic landscape, leading to treatment challenges and frequent relapses. Measurable residual disease (MRD) testing has become a standard in…
…and surface protein expression. We show here complex clonal evolution of MM in two patient samples as copy gains and losses were sequentially acquired and correlated with expression changes of…
…(homozygous, heterozygous, compound heterozygous), and their phenotypic effects all contribute to the layer of complexity to the mosaicism of editing’s outcomes. Current genome editing analyses primarily rely on bulk methods…
…edit, off-target edits, translocations between predicted edit sites, as well as the genomic CNV landscape in over thousands of cells in parallel. This single-cell technology offers a comprehensive view of…
Sample multiplexing allows multiple samples to be pooled and processed simultaneously in a single run on the Tapestri Platform to achieve higher throughput and cost-efficiency while maintaining the same robust…
Sample multiplexing allows multiple samples to be pooled and processed simultaneously in a single run on the Tapestri Platform to achieve higher throughput and cost-efficiency while maintaining the same robust…
Tapestri single-cell multiomics analysis can transform how you tackle the complexities of multiple myeloma (MM) and its precursor stages by integrating genomic, proteomic, and clonotypic subclonal assessment with single-cell resolution,…
…to Tapestri while highlighting the power of the GE solution. The combination of these two innovative solutions creates an indispensable tool that equips researchers to unravel the intricacies of genome…
…(PDXs) represent a groundbreaking approach that has reshaped our capacity to investigate, comprehend, and address diseases. Leveraging the synergy of single-cell DNA sequencing and PDXs has empowered us to unveil…
…long-term surveillance. Being able to more comprehensively identify low-frequency subclones that may result in frank disease or resistance would enable more direct application of precision therapies. Here, we present proof…
…from the diagnostic population. These methods are commonly discordant, leading to clinical questions for individual surveillance and treatment. Combining these assays with single-cell resolution overcomes these limitations and reveals subclonal…
…long-term surveillance. Being able to more comprehensively identify low frequency subclones that may result in frank disease or resistance would enable more direct application of precision therapies. Here, we present…
